Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
暂无分享,去创建一个
Eric P. Hoffman | Pat Furlong | Craig McDonald | Robert Kirk DeLisle | Yetrib Hathout | Larry Gold | David G. Sterling | Heather Gordish-Dressman | Erik Henricson | L. Gold | E. Hoffman | Y. Hathout | H. Sweeney | E. Brody | L. Cripe | R. K. DeLisle | C. McDonald | A. Lorts | S. Nelson | Malti Nikrad | B. Singer | H. Gordish-Dressman | Yvonne M. Kobayashi | P. Clemens | J. Mah | H. Lee Sweeney | Jean K. Mah | David Sterling | Edward Brody | Paula R. Clemens | Linda Cripe | Lauren Hache | Yvonne Monique Kobayashi | Angela Lorts | Bob Mehler | Sally Nelson | Malti Nikrad | Britta Singer | Fintan Steele | Steve Williams | P. Furlong | E. Henricson | L. Hache | J. Mah | F. Steele | H. Sweeney | Stephen E. Williams | Bob Mehler | E. P. Hoffman
[1] Daniel O'Connell,et al. Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets , 2012, Proceedings of the National Academy of Sciences.
[2] H. Sweeney,et al. Systemic Myostatin Inhibition via Liver-Targeted Gene Transfer in Normal and Dystrophic Mice , 2010, PloS one.
[3] B. Wong,et al. Corticosteroids in Duchenne Muscular Dystrophy: A Reappraisal , 2002, Journal of child neurology.
[4] E. Hoffman,et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects , 2013, EMBO molecular medicine.
[5] S. Peltz,et al. Ataluren as an agent for therapeutic nonsense suppression. , 2013, Annual review of medicine.
[6] Larry Gold,et al. Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.
[7] Tracy R. Keeney,et al. Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.
[8] E. Lee,et al. Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse , 2014, Arthritis Research & Therapy.
[9] Kristy Brown,et al. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. , 2014, Human molecular genetics.
[10] B. Lin,et al. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders , 2013, Current opinion in supportive and palliative care.
[11] K. Lim,et al. Eteplirsen in the treatment of Duchenne muscular dystrophy , 2017, Drug design, development and therapy.
[12] S. Peltz,et al. THE 6-MINUTE WALK TEST AND OTHER ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: LONGITUDINAL NATURAL HISTORY OBSERVATIONS OVER 48 WEEKS FROM A MULTICENTER STUDY , 2013, Muscle & nerve.
[13] G. van Ommen,et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.
[14] R. Butowt,et al. GDNF increases the survival of developing oculomotor neurons through a target-derived mechanism , 2003, Molecular and Cellular Neuroscience.
[15] J. Bourke,et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.
[16] Thomas E. Edwards,et al. Crystal Structure of Interleukin-6 in Complex with a Modified Nucleic Acid Ligand , 2014, The Journal of Biological Chemistry.
[17] Juan Li,et al. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. , 2008, Human gene therapy.
[18] B. Alman,et al. The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy , 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[19] R. Finkel,et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.
[20] Jay J. Han,et al. The cooperative international neuromuscular research group duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used , 2013, Muscle & nerve.
[21] D. Schneider,et al. Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor , 2014, The Journal of Biological Chemistry.
[22] Richard T. Lee,et al. Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy , 2013, Cell.
[23] E. Hoffman,et al. Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. , 2012, Physical medicine and rehabilitation clinics of North America.
[24] E. Bertini,et al. Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies , 2014, EMBO molecular medicine.
[25] Steven A Carr,et al. Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.
[26] A. Ferlini,et al. Biomarkers and surrogate endpoints in Duchenne: Meeting report , 2014, Neuromuscular Disorders.
[27] E. Hoffman,et al. Phospholipase A2 activity in dystrophinopathies , 1995, Neuromuscular Disorders.
[28] Nathalie Jette,et al. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy , 2014, Neuromuscular Disorders.
[29] K. Davies,et al. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches , 2013, Nature Reviews Genetics.
[30] Eric P Hoffman,et al. Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. , 2013, Discovery medicine.
[31] Jay J. Han,et al. The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measur , 2013, Muscle & nerve.
[32] K. Wagner,et al. Therapeutic advances in muscular dystrophy , 2013, Annals of neurology.
[33] A. Manzur,et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2004, The Cochrane database of systematic reviews.
[34] J. Mendell,et al. Dystrophin immunity in Duchenne's muscular dystrophy. , 2010, The New England journal of medicine.
[35] L. Popplewell,et al. New developments in the use of gene therapy to treat Duchenne muscular dystrophy , 2014, Expert opinion on biological therapy.
[36] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[37] Eric P. Hoffman,et al. Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.
[38] Yun‐Sil Lee,et al. Regulation of GDF-11 and myostatin activity by GASP-1 and GASP-2 , 2013, Proceedings of the National Academy of Sciences.
[39] J. Ervasti,et al. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin , 1993, The Journal of cell biology.
[40] N. Anderson,et al. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. , 2010, Clinical chemistry.
[41] T. Khurana,et al. Myostatin propeptide‐mediated amelioration of dystrophic pathophysiology , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[42] Jay J. Han,et al. The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy , 2010, Muscle & nerve.
[43] Larry Gold,et al. Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents , 2014, Molecular therapy. Nucleic acids.
[44] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .